Oramed Pharmaceuticals (Seite 1964)
eröffnet am 28.03.07 10:26:47 von
neuester Beitrag 07.05.24 21:17:15 von
neuester Beitrag 07.05.24 21:17:15 von
Beiträge: 19.668
ID: 1.121.564
ID: 1.121.564
Aufrufe heute: 0
Gesamt: 1.542.730
Gesamt: 1.542.730
Aktive User: 0
ISIN: US68403P2039 · WKN: A1CTNU · Symbol: ORMP
2,3400
USD
+0,86 %
+0,0200 USD
Letzter Kurs 25.05.24 Nasdaq
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,0000 | +99.999,00 | |
| 0,9998 | +122,18 | |
| 0,8970 | +75,20 | |
| 0,8680 | +31,54 | |
| 2,0600 | +24,85 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 49,24 | -9,67 | |
| 2,9800 | -13,12 | |
| 4,8500 | -14,31 | |
| 0,6460 | -19,25 | |
| 1,3500 | -25,21 |
Beitrag zu dieser Diskussion schreiben
Feedback
Schade das Oramed vorher noch keiner entdeckt hat 
Im Team von Oramed sitzen einige Jahre Erfahrung! 
Wenn das kein gutes Zeichen ist!
Great scientific minds with more than 25 years of experience
Miriam Kidron, PhD
Dr. Miriam Kidron is a pharmacologist and a biochemist with a PhD in biochemistry. From 1990 to the present time, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. She was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award.
Scientific Board:
Derek LeRoith MD PhD is currently the Chief of the Division of Endocrinology, Diabetes and Bone Diseases at Mt. Sinai School of Medicine, NY.
Dr. LeRoith has worked at the NIH since 1979 in the field of Endocrinology and Diabetes and rose to be Diabetes Branch at the National Institutes of Health in Bethesda MD, a position he held until 2005.
His main interests have focused on the role of insulin and the insulin-like growth factors in normal physiology and disease states. In these areas he has published over 500 peer-reviewed articles and reviews in high profile journals. He is also the senior editor of a textbook on Diabetes, now in its third edition and has edited books on the insulin-like growth factors.
He has made major contributions in our understanding of the basic pathophysiology of type 2 diabetes and also the role of the IGFs in various disorders especially in cancer, and is considered a world expert on these topics.
In recognition of his contributions he has received many lectureships worldwide and has been the plenary speaker at numerous national and international symposia.
He is the editor of a number of diabetes- and growth factor-related journals, has been on the advisory boards of a number of companies and co-chairs two national committees that deal with the education of endocrinologist and primary care physicians.
Itamar Raz, M.D. is a professor of Internal Medicine at Hadassah University Medical Center and the head of the Diabetes Unit and Research Center at Hadassah. He also serves as the head of the Israel National Council of Diabetes and president of D-Cure, a foundation that supports research in the field of diabetes. As president of the Israel Diabetes Research Group, he collaborates with 18 other diabetologists in Israel, conducting clinical research aimed at improving the treatment of diabetic patients. Professor Raz serves on the steering committee of several large international clinical studies.
In addition, he serves on several advisory boards and is a member of several editorial boards, including the Israeli Medical Association Journal (IMAJ).
Professor Raz has published extensively in the area of diabetes mellitus with over 170 publications to his credit. Professor Raz's research interests have focused on the pathologic mechanisms leading to diabetic complications, mainly the relationship to vasoactive peptide. A large part of his research is searching for the pathophysiology of beta cell dysfunction and loss in diabetes.
Dr. Brazilai
Dr. Ferrannini
Supported by a strong management team:
Nadav Kidron, CEO
Mr. Kidron is an entrepreneur whose expertise includes senior executive roles in a wide range of industries. He graduated from Bar-Ilan University in Israel with a Bachelor of Law Degree. He is a member of the Israeli bar association and is currently working towards his MBA.
George Drazenovic, CFO
Mr. Drazenovic has over 10 years of experience in accounting, financial management and financial reporting. Most recently, he was the CFO for a public energy technology company with a market capitalization in excess of US $60 million. Mr. Drazenovic is a CFA, CGA and holds an MBA from the University of Notre Dame (US) and a BA in Economics from the University of British Columbia (Canada).
Wenn das kein gutes Zeichen ist!
Great scientific minds with more than 25 years of experience
Miriam Kidron, PhD
Dr. Miriam Kidron is a pharmacologist and a biochemist with a PhD in biochemistry. From 1990 to the present time, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. She was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award.
Scientific Board:
Derek LeRoith MD PhD is currently the Chief of the Division of Endocrinology, Diabetes and Bone Diseases at Mt. Sinai School of Medicine, NY.
Dr. LeRoith has worked at the NIH since 1979 in the field of Endocrinology and Diabetes and rose to be Diabetes Branch at the National Institutes of Health in Bethesda MD, a position he held until 2005.
His main interests have focused on the role of insulin and the insulin-like growth factors in normal physiology and disease states. In these areas he has published over 500 peer-reviewed articles and reviews in high profile journals. He is also the senior editor of a textbook on Diabetes, now in its third edition and has edited books on the insulin-like growth factors.
He has made major contributions in our understanding of the basic pathophysiology of type 2 diabetes and also the role of the IGFs in various disorders especially in cancer, and is considered a world expert on these topics.
In recognition of his contributions he has received many lectureships worldwide and has been the plenary speaker at numerous national and international symposia.
He is the editor of a number of diabetes- and growth factor-related journals, has been on the advisory boards of a number of companies and co-chairs two national committees that deal with the education of endocrinologist and primary care physicians.
Itamar Raz, M.D. is a professor of Internal Medicine at Hadassah University Medical Center and the head of the Diabetes Unit and Research Center at Hadassah. He also serves as the head of the Israel National Council of Diabetes and president of D-Cure, a foundation that supports research in the field of diabetes. As president of the Israel Diabetes Research Group, he collaborates with 18 other diabetologists in Israel, conducting clinical research aimed at improving the treatment of diabetic patients. Professor Raz serves on the steering committee of several large international clinical studies.
In addition, he serves on several advisory boards and is a member of several editorial boards, including the Israeli Medical Association Journal (IMAJ).
Professor Raz has published extensively in the area of diabetes mellitus with over 170 publications to his credit. Professor Raz's research interests have focused on the pathologic mechanisms leading to diabetic complications, mainly the relationship to vasoactive peptide. A large part of his research is searching for the pathophysiology of beta cell dysfunction and loss in diabetes.
Dr. Brazilai
Dr. Ferrannini
Supported by a strong management team:
Nadav Kidron, CEO
Mr. Kidron is an entrepreneur whose expertise includes senior executive roles in a wide range of industries. He graduated from Bar-Ilan University in Israel with a Bachelor of Law Degree. He is a member of the Israeli bar association and is currently working towards his MBA.
George Drazenovic, CFO
Mr. Drazenovic has over 10 years of experience in accounting, financial management and financial reporting. Most recently, he was the CFO for a public energy technology company with a market capitalization in excess of US $60 million. Mr. Drazenovic is a CFA, CGA and holds an MBA from the University of Notre Dame (US) and a BA in Economics from the University of British Columbia (Canada).
In Frankfurt schon 57.000 Stücke gehandelt. Das Interesse scheint groß zu sein.
Hier nochmal der Link zur heutigen Empfehlung:
http://www.wallstreet-online.de/adserver/code.php?bid=11360
http://www.wallstreet-online.de/adserver/code.php?bid=11360
Research and Development
Making insulin delivery in tablet form a reality
The ability to correctly self-administer doses of insulin is crucial to the long-term health of diabetics. For years, the only method patients had to deliver insulin to their bodies was by injection. But, years of research by Oramed’s highly respected team of scientists discovered a technology at the Hadassah University Hospital that has the potential to change all of that.
Up until now, the idea of insulin pills or tablets was inconceivable due to the fact that insulin, which is a protein, breaks down in the digestive system. However, Oramed’s patented technology overcame the problem of digestion as well as permeability to the intestine. This has been a major hurdle that has inhibited the development of an orally ingestible insulin for decades.
Prof. Hanoch Bar-On, a leading Diabetologist on the Oramed team, states that the route of the insulin from the swallowed pill “imitates nature” in that it passes to the liver and then to the bloodstream. Injected insulin goes straight to the bloodstream.
Preclinical studies on animals were successful, and the Oramed team is preparing for phase one clinical trials in the near future.
Making insulin delivery in tablet form a reality
The ability to correctly self-administer doses of insulin is crucial to the long-term health of diabetics. For years, the only method patients had to deliver insulin to their bodies was by injection. But, years of research by Oramed’s highly respected team of scientists discovered a technology at the Hadassah University Hospital that has the potential to change all of that.
Up until now, the idea of insulin pills or tablets was inconceivable due to the fact that insulin, which is a protein, breaks down in the digestive system. However, Oramed’s patented technology overcame the problem of digestion as well as permeability to the intestine. This has been a major hurdle that has inhibited the development of an orally ingestible insulin for decades.
Prof. Hanoch Bar-On, a leading Diabetologist on the Oramed team, states that the route of the insulin from the swallowed pill “imitates nature” in that it passes to the liver and then to the bloodstream. Injected insulin goes straight to the bloodstream.
Preclinical studies on animals were successful, and the Oramed team is preparing for phase one clinical trials in the near future.
Trading Spotlight
Die bisherigen Resultate bezeichnete die Firma als extrem ermutigend, so dass die Oramed, welche die Patente bezüglich der Technologie zur oralen Einnahme von Insulin von der Hadasit Medical Services im Februar 2006 erwarb, die Phase I beim israelischen Gesundheitsministerium bereits beantragen konnte.
Das Gesundheitsministerium und das Hadassah Medical Center Insitutional Review Board haben nach eingehender Überprüfung der vorliegenden Daten, sowie der Überprüfung der geplanten Phase I, der Oramed grünes Licht gegeben.
Das Gesundheitsministerium und das Hadassah Medical Center Insitutional Review Board haben nach eingehender Überprüfung der vorliegenden Daten, sowie der Überprüfung der geplanten Phase I, der Oramed grünes Licht gegeben.
Mir geht es auch nicht anders 
Antwort auf Beitrag Nr.: 28.538.157 von Nina_Trader am 28.03.07 11:08:55
Cooles Video!
Verstehe aber leider nur die Hälfte
Cooles Video!
Verstehe aber leider nur die Hälfte
Antwort auf Beitrag Nr.: 28.538.549 von xTRADERx am 28.03.07 11:23:57New Cantech hatte ich mal! Dann habe ich verkauft und bin gut rausgekommen!
Verfolge den Brief schon länger. Einige Aktien laufen klasse. Bin nicht bei allen dabei. Wenn mir die Story gefällt ok, dann kaufe ich auch. Die meisten sind bei mir im Plus. Klar hat man immer mal ne Kacke dabei aber das ist an der Börse normal!
Verfolge den Brief schon länger. Einige Aktien laufen klasse. Bin nicht bei allen dabei. Wenn mir die Story gefällt ok, dann kaufe ich auch. Die meisten sind bei mir im Plus. Klar hat man immer mal ne Kacke dabei aber das ist an der Börse normal!
Antwort auf Beitrag Nr.: 28.538.133 von Zocker_Freak am 28.03.07 11:07:42Ich hab auch noch New Cantech drin.
War auch ein Tipp von den Jungs von Pearlsfactory als die noch fast keiner auf der Watchlist hatte (bei 0,35 EUR glaub ich) und danach hagelte es nur so Empfehlungen....wer weiß, vielleicht diesmal wieder ähnlich???
Und auch von der Performance her bin ich größtenteils mit denen zufrieden, wenige Looser, einige auf stabilem Niveau und NCV bei über 100% im grünen Bereich.
Lob! Weiter so Jungs.
Greetz
xTRADERx
Do your own DD!
War auch ein Tipp von den Jungs von Pearlsfactory als die noch fast keiner auf der Watchlist hatte (bei 0,35 EUR glaub ich) und danach hagelte es nur so Empfehlungen....wer weiß, vielleicht diesmal wieder ähnlich???
Und auch von der Performance her bin ich größtenteils mit denen zufrieden, wenige Looser, einige auf stabilem Niveau und NCV bei über 100% im grünen Bereich.
Lob! Weiter so Jungs.
Greetz
xTRADERx
Do your own DD!
Durchsuchen
Oramed Pharmaceuticals
